Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report

Henry,Théophraste; Fabre,Elizabeth; Baccar,Laurent  S.; Lamuraglia,Michele

doi:10.3892/mco.2019.1797

Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report

Authors:
- Théophraste Henry
- Elizabeth Fabre
- Laurent S. Baccar
- Michele Lamuraglia
View Affiliations

Affiliations: Assistance Publique‑Hôpitaux de Paris, Louis Mourier Hospital, Medical Oncology Unit, Department of Medicine, 92700 Colombes, France, Assistance Publique‑Hôpitaux de Paris, Hôpital Européen George Pompidou, Department of Medical Oncology, 75908 Paris, France, Assistance Publique‑Hôpitaux de Paris, Louis Mourier Hospital, Department of Radiology, 92700 Colombes, France, Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale (LIB), Assistance Publique‑Hôpitaux de Paris, Hôpital Beaujon, 75006 Paris, France
Published online on: January 7, 2019 https://doi.org/10.3892/mco.2019.1797
Pages: 387-390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trabectedin (ET‑743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. In the present case report, two patients with advanced and metastatic uterine leiomyosarcomas (ULMS) with significant progression‑free survival (PFS) and overall survival (OS) administered Trabectedin as second and third line treatment are reported. The first case received third line Trabectedin with a PFS of 24 months and an OS of 35 months. The second case received second line Trabectedin with a PFS of 24 months and an OS of 30 months. In addition, a good safety record was obtained in the long‑term administration of Trabectedin (more so in case 1 than case 2), with a good quality of life.

View Figures

View References

1	D'Angelo E, Espinosa I, Ali R, Gilks CB, Rijn Mv, Lee CH and Prat J: Uterine leiomyosarcomas: Tumor size, mitotic index and biomarkers Ki67 and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 121:328–333. 2011. View Article : Google Scholar : PubMed/NCBI
2	Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, Michels JJ, Blay JY, Coindre JM and Bui B: Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 117:1049–1054. 2011. View Article : Google Scholar : PubMed/NCBI
3	Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY and Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: Analysis of publications from the last 10 years. Ann Oncol. 22:1266–1272. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lin G, Yang LY, Huang YT, Ng KK, Ng SH, Ueng SH, Chao A, Yen TC, Chang TC and Lai CH: Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma/smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging. 43:333–342. 2016. View Article : Google Scholar : PubMed/NCBI
5	Giuntoli RL II, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney G and Gostout BS: Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management and adjuvant therapy. Gynecol Oncol. 89:460–469. 2003. View Article : Google Scholar : PubMed/NCBI
6	Gupta AA, Yao X, Verma S, Mackay H and Hopkins L: Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group: Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: A systematic review. Clin Oncol (R Coll Radiol). 25:346–355. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gupta AA, Yao X, Verma S, Mackay H and Hopkins L: Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: A clinical practice guideline. Curr Oncol. 20:e448–e454. 2013. View Article : Google Scholar : PubMed/NCBI
8	Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ and Hensley ML: A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol. 124:48–52. 2012. View Article : Google Scholar : PubMed/NCBI
9	Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, et al: Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): A non-randomised, multicentre, phase 2 trial. Lancet Oncol. 16:457–464. 2015. View Article : Google Scholar : PubMed/NCBI